JPWO2019222157A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222157A5 JPWO2019222157A5 JP2021514292A JP2021514292A JPWO2019222157A5 JP WO2019222157 A5 JPWO2019222157 A5 JP WO2019222157A5 JP 2021514292 A JP2021514292 A JP 2021514292A JP 2021514292 A JP2021514292 A JP 2021514292A JP WO2019222157 A5 JPWO2019222157 A5 JP WO2019222157A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- pharmaceutically acceptable
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 6
- -1 amino, hydroxyl Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 108030001712 Macrophage elastases Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023140718A JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| US62/671,753 | 2018-05-15 | ||
| PCT/US2019/032131 WO2019222157A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023140718A Division JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523241A JP2021523241A (ja) | 2021-09-02 |
| JP2021523241A5 JP2021523241A5 (https=) | 2022-03-15 |
| JPWO2019222157A5 true JPWO2019222157A5 (https=) | 2022-03-15 |
| JP7343571B2 JP7343571B2 (ja) | 2023-09-12 |
Family
ID=66690981
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514292A Active JP7343571B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2021514291A Active JP7344959B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514291A Active JP7344959B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20190352288A1 (https=) |
| EP (4) | EP4335499A3 (https=) |
| JP (4) | JP7343571B2 (https=) |
| KR (3) | KR102861502B1 (https=) |
| CN (3) | CN112424186A (https=) |
| AU (3) | AU2019269409B2 (https=) |
| BR (1) | BR112020023269A2 (https=) |
| CA (2) | CA3100320A1 (https=) |
| DK (2) | DK3793995T3 (https=) |
| ES (2) | ES2978192T3 (https=) |
| FI (2) | FI3793992T3 (https=) |
| HU (2) | HUE066619T2 (https=) |
| LT (1) | LT3793995T (https=) |
| MY (1) | MY199200A (https=) |
| PL (1) | PL3793995T3 (https=) |
| PT (2) | PT3793992T (https=) |
| SG (2) | SG11202011316RA (https=) |
| SI (1) | SI3793995T1 (https=) |
| TW (3) | TWI827601B (https=) |
| WO (2) | WO2019222157A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| SI3793995T1 (sl) | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| TW202313011A (zh) * | 2021-06-08 | 2023-04-01 | 逸達生物科技股份有限公司 | Mmp抑制劑於治療急性呼吸窘迫綜合症之用途 |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| EP1150975A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| JP2004527511A (ja) | 2001-03-15 | 2004-09-09 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| JP5042833B2 (ja) | 2004-08-19 | 2012-10-03 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体 |
| EP2797002A4 (en) | 2011-12-21 | 2015-05-20 | Panasonic Corp | DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD |
| SI3793995T1 (sl) * | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
-
2019
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 EP EP24150920.7A patent/EP4349332A3/en active Pending
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523241A5 (https=) | ||
| FI3793995T3 (fi) | Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| CN113365997A (zh) | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 | |
| JP2020521741A5 (https=) | ||
| JP2020523351A5 (https=) | ||
| CN110582489A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2010540525A5 (https=) | ||
| JP2008509146A5 (https=) | ||
| JP2017518959A5 (https=) | ||
| MY152955A (en) | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | |
| JP2012500260A5 (https=) | ||
| JP2019504898A5 (https=) | ||
| JP2015500307A5 (https=) | ||
| JP2011507929A5 (https=) | ||
| JP2021523240A5 (https=) | ||
| JP2021512114A5 (https=) | ||
| JP2010540593A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| RU2009102943A (ru) | Производные фенола для лечения респираторных заболеваний | |
| JPWO2019222157A5 (https=) | ||
| JP2017522348A5 (https=) | ||
| JP2020531593A5 (https=) | ||
| JP2020521766A5 (https=) | ||
| JP2016532669A5 (https=) |